跳至主要内容
临床试验/NCT03218722
NCT03218722已完成3 期

Impact of Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma

University Hospital, Grenoble12 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2017年12月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
350
试验地点
12
主要终点
Labile blood products transfused in the first 24 hours

研究概览

简要总结

Acute traumatic coagulopathy (ATC) is common in severe trauma patients (around 25 to 30% of patients with severe trauma) and is associated with increased mortality. ATC is associated with fibrinogen and clotting factors deficiencies. Therefore, ATC management relies on early administration of fibrinogen and blood products in case of massive transfusion with a 1:1 or 1:2 ratio between Fresh Frozen Plasma (FFP) and Red Blood Cells (RBC). This strategy relies on fast supply of FFP.

To overcome delay for FFP ordering, transport and defrosting, the PROCOAG study proposes to use prothrombrin concentrate complex (PCC) as alternative to treat coagulation factor deficiency. PCC is readily available upon hospital arrival. In addition to fibrinogen treatment, it is thought that PCC can be efficient in ATC management, while reducing risks associated with massive transfusion.

ProCoag is a randomized, controlled, double-blinded, parallel clinical trial aiming at showing superiority of early PPC+ fibrinogen strategy on fibrinogen only strategy for the management of patients at risk of massive transfusion.

Early administration of PPC should optimize patient blood management and therefore reduce blood products transfused within the first 24 hours following a severe trauma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Primary admission for a severe trauma
  • Out-of-hospital transfusion or RBC transfusion within the first hour following hospital admission
  • Clinical prediction or ABC score (Assessment of Blood Consumption) ≥ 2 of massive transfusion defined by a transfusion of at least 10 CGR during the first 24 hours or 3 CGR during the first hour.
  • Informed consent signed by a relative or emergency procedure

排除标准

  • Cardiac arrest before randomisation
  • Secondary transfer from another hospital (a technical stop is accepted)
  • Post-traumatic lesions out of therapeutic resources with death expected in the hour following hospital admission
  • Anti-coagulation treatment (K anti-vitamine, new oral anticoagulant)
  • Pregnancy
  • Hypersensitivity to active substances or one of the excipients of KANOKAD®
  • Patient treated with an experimental medicine within the last 30 days
  • Decision of therapeutic limitation before randomisation
  • Patient protected by article L1121-7 of the French Public health code.
  • Knowledge of a contraindication to the use of NaCl 0.9% at the dose of 1 mg/kg (hyperchloremia, hypernatremia...)

研究组 & 干预措施

PCC treatment

Experimental

Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)

干预措施: Pro-Thrombin Concentrate Complex (Drug)

Placebo treatment

Placebo Comparator

Conventional strategy for ATC management without PCC (NaCl 0.9%)

干预措施: NaCl 0.9% (Drug)

结局指标

主要结局

Labile blood products transfused in the first 24 hours

时间窗: 24 hours following hospital admission

This outcome is measured in number of bags administered

次要结局

  • Hospitalisation status(Day 28)
  • Cost of the strategy(Day 8 and Day 28)
  • RBC (Red Blood Cells) transfused in the first 24 hours(24 hours following hospital admission)
  • Platelets transfused in the first 24 hours(24 hours following hospital admission)
  • Time to hemostasis(Within the first 24 hours following admission)
  • Thrombo-embolic events(ICU stay (an average of 28 days))
  • Mortality(24 hours and Day 28)
  • ICU-free days(Hospital stay (an average of 28 days))
  • Ventilator-Free Days(ICU stay (an average of 21 days))
  • Hospital-free days(Within the first 28 days)
  • Glasgow Outcome Scale Extended (GOSE)(Day 28)
  • FFP transfused in the first 24 hours(24 hours following hospital admission)
  • Time to achieve Prothrombin ratio < 1.5(Within the first 24 hours)

研究者

发起方
University Hospital, Grenoble
申办方类型
Other
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验